Once-daily multilayer-release methylphenidate in a double-blind, crossover comparison to immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder

Journal of Child and Adolescent Psychopharmacology

Volumn 17, Issue 5, 2007, Pages 675-688

  Weiss, Margaret ^a   Hechtman, Lily ^b   Turgay, Atilla ^c   Jain, Umesh ^d   Quinn, Declan ^e   Ahmed, Tahira S ^f   Yates, Timothy ^g   Reiz, Joseph L ^h   Donnelly, Graeme A E ^h   Harsanyi, Zoltan ^h   Darke, Andrew C ^h  

^a CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

^b MONTREAL CHILDREN S HOSPITAL   (Canada)

^c SCARBOROUGH HOSPITAL   (Canada)

^d CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^e ROYAL UNIVERSITY HOSPITAL   (Canada)

^f ADD Clinic   (Canada)

^g UNIVERSITY OF CALGARY   (Canada)

^h PURDUE PHARMA L P   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIPHENTIN; METHYLPHENIDATE; UNCLASSIFIED DRUG;

ADOLESCENT; ANOREXIA; APATHY; ARTICLE; ASTHENIA; ASTHMA; ATTENTION DEFICIT DISORDER; CHILD PSYCHIATRY; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DECREASED APPETITE; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG DOSAGE FORM COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EUPHORIA; FEMALE; HEADACHE; HUMAN; INCREASED APPETITE; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MENTAL INSTABILITY; MOTOR DYSFUNCTION; NAUSEA; NERVOUSNESS; OPEN STUDY; PHARYNGITIS; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REBOUND; SCHOOL CHILD; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SYNCOPE; TIC;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CROSS-OVER STUDIES; DATA INTERPRETATION, STATISTICAL; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; METHYLPHENIDATE; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME;

EID: 35848954754     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2006.0101     Document Type: Article

References (35)

1. Barkley RA, Edelbrock C: Assessing situational variation in children's problem behaviours: The Home and School Situations Questionnaires. Adv Behav Assess Child Fam 4:157-176, 1987.
2. Biederman J, Quinn D, Weiss M, Markabi S, Weidenman M, Edson K, Karlsson G, Pohlmann H, Wigal S: Efficacy and safety of Ritalin LA, a new, once daily, extended-release dosage form of methylphenidate, in children with attention deficit hyperactivity disorder. Paediatr Drugs 5:833-841, 2003.
3. Brown RT, Borden KA, Clingerman SR: Adherence to methylphenidate therapy in a pediatric population: A preliminary investigation. Psychopharmacol Bull 21:28-36, 1985.
4. Bussing R, Zima BT, Mason D, Hou W, Garvan CW, Forness S: Use and persistence of pharmacotherapy for elementary school students with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 15:78-87, 2005.
5. st ed. Toronto, Canadian ADD Resource Alliance, 2006.
6. Conners CK, Sitarenios G, Parker JD, Epstein JN: Revision and restandardization of the Conners' Teacher Rating Scale (CTRS-R): Factor structure, reliability and criterion validity. J Abnorm Child Psychol 26:279-291, 1998a.
7. Conners CK, Sitarenios G, Parker JD, Epstein JN: The revised Conners' Parent Rating Scale (CPRS-R): Factor structure, reliability and criterion validity. J Abnorm Child Psychol 26:257-268, 1998b.
8. Firestone P: Factors associated with children's adherence to stimulant mediation. Am J Orthopsychiatry 52:447-457, 1982.
9. Greenhill LL, Vitiello B, Fisher P, Levine J, Davies M, Abikoff H, Chrisman AK, Chuang S, Findling RL, March J, Scahill L, Walkup J, Riddle MA: Comparison of increasingly detailed elicitation methods for the assessment of adverse events in pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry 43:1488-1496, 2004.
10. Jacob J, Adesman A, Solanto M, Dimino R: Shortcomings of the short version of the Conners' rating scales (revised) for diagnosis of ADHD, predominantly inattentive type. Toronto (Ontario), American Academy of Child & Adolescent Psychiatry (AACAP) Annual Meeting, 2005 (abstract).
11. Jain U, Hechtman L, Weiss M, Ahmed TS, Reiz JL, Donnelly GAE, Harsanyi Z, Darke AC: Efficacy of a novel biphasic controlled-release methylphenidate formula in adults with attention-deficit/hyperactivity disorder: Results of a double-blind, placebo-controlled crossover study. J Clin Psychiatry 68:268-277, 2007.
12. Jensen PS, Hinshaw SP, Swanson JM, Greenhill LL, Conners CK, Arnold LE, Abikoff HB, Elliott G, Hechtman L, Hoza B, March JS, Newcorn JH, Severe JB, Vitiello B, Wells K, Wigal T: Findings from the NIMH multimodal treatment study of ADHD (MTA): Implications and applications for primary care providers. J Dev Behav Pediatr 22:60-73, 2001.
13. Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, Williamson D, Ryan N: Schedule for affective disorders and schizophrenia for school-age children-present and lifetime version (K-SADS-PL): Initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 36:980-988, 1997.
14. Klassen A, Miller A, Raina P, Lee SK, Olsen L: Attentiondeficit hyperactivity disorder in children and youth: A quantitative systematic review of the efficacy of different management strategies. Can J Psychiatry 44:1007-1016, 1999.
15. Klassen AF, Miller A, Fine S: Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder. Pediatrics 114:e541-e547, 2004.
16. Konrad K, Gunther T, Hanisch C, Herpertz-Dahlmann B: Differential effects of methylphenidate on attentional functions in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 43:191-198, 2004.
17. Lopez F, Silva R, Pestreich L, Muniz R: Comparative efficacy of two once daily methylphenidate formulations (Ritalin LA and Concerta) and placebo in children with attention deficit hyperactivity disorder across the school day. Paediatr Drugs 5:545-555, 2003.
18. Matza LS, Rentz AM, Secnik K, Swensen AR, Revicki DA, Michelson D, Spencer T, Newcorn JH, Kratochvil CJ: The link between health-related quality of life and clinical symptoms among children with attention-deficit hyperactivity disorder. J Dev Behav Pediatr 25:166-174, 2004.
19. Miller AR, Lalonde CE, McGrail KM: Children's persistence with methylphenidate therapy: A population-based study. Can J Psychiatry 49:761-788, 2004.
20. National Institute of Mental Health: CGI (Clinical Global Impressions Scale). Psychopharmacol Bull 21:839-844, 1985.
21. Newcorn JH, Spencer TJ, Biederman J, Milton DR, Michelson D: Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. J Am Acad Child Adolesc Psychiatry 44:240-248, 2005.
22. Patrick KS, Gonzalez MA, Straughn AB, Markowitz JS: New methylphenidate formulations for the treatment of attention-deficit/hyperactivity disorder. Expert Opin Drug Deliv 2:121-143, 2005.
23. Pelham WE, Gnagy EM, Burrows-Maclean L, Williams A, Fabiano GA, Morrisey SM, Chronis AM, Forehand GL, Nguyen CA, Hoffman MT, Lock TM, Fielbelkorn K, Coles EK, Panahon CJ, Steiner RL, Meichenbaum DL, Onyango AN, Morse GD: Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 107:e105, 2001.
24. Purdue Pharma Canada: Biphentin® (methylphenidate HCl) Product Monograph. Pickering (Ontario), ON: Purdue Pharma, 2006.
25. Quinn D, Bode T, Reiz JL, Donnelly GAE, Darke AC: Single dose pharmacokinetics of multilayer-release methylphenidate and immediate-release methylphenidate in children with ADHD. J Clin Pharmacol 47:760-766, 2007.
26. Schachar R, Ickowicz A: Pharmacological treatment of attention deficit hyperactivity disorder. In: Handbook of Disruptive Behavior Disorders. Edited by Quay HC, Nogan AE. New York (New York), Kluwer Boston, Inc, 1999.
27. Schachar R, Ickowicz A, Crosbie J, Donnelly GAE, Reiz JL, Miceli PC, Harsanyi Z, Darke AC: Cognitive and behavioral effects of multilayer-release methylphenidate in the treatment of children with attention-deficit/ hyperactivity disorder. J Child Adolesc Psychopharmacol (in press), 2007.
28. Schachter HM, Pham Ba, King J, Langford S, Moher D: How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. CMAJ 165:1475-1488, 2001.
29. Serra-Pinheiro MA, Mattos P, Souza I, Pastura G, Gomes F: The effect of methylphenidate on oppositional defiant disorder comorbid with attention deficit/hyperactivity disorder. Arq Neuropsiquiatr 62:399-402, 2004.
30. Steele M, Weiss M, Swanson J, Wang J, Prinzo RS, Binder CE: A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attentiondeficit/hyperactivity disorder. Can J Clin Pharmacol 13:e50-e62, 2006.
31. Swanson JM, Kraemer HC, Hinshaw SP, Arnold LE, Conners CK, Abikoff HB, Clevenger W, Davies M, Elliott GR, Greenhill LL, Hechtman L, Hoza B, Jensen PS, March JS, Newcorn JH, Owens EB, Pelham WE, Schiller E, Severe JB, Simpson S, Vitiello B, Wells K, Wigal T, Wu M: Clinical relevance of the primary findings of the MTA: Success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Am Acad Child Adolesc Psychiatry 40:168-179, 2001.
32. Swanson JM, Wigal SB, Wigal T, Sonuga-Barke E, Greenhill LL, Biederman J, Kollins S, Nguyen AS, DeCory HH, Hirshe Dirksen SJ, Hatch SJ, COMACS Study Group: A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the COMACS study). Pediatrics 113:e206-e216, 2004.
33. Tannock R, Schachar R, Logan G: Methylphenidate and cognitive flexibility: Dissociated dose effects in hyperactive children. J Abnormal Child Psychology 23:235-266, 1995.
34. Wolraich ML, Greenhill LL, Pelham W, Swanson J, Wilens T, Palumbo D, Atkins M, McBurnett K, Bukstein O, August G: Randomized, controlled trial of OROS methylphenidate once a day in children with attention-deficit/hyperactivity disorder. Pediatrics 108:883-892, 2001.
35. Zimmerman ILL, Woo-SAM JM: Review of the criterionrelated validity of the WISC-III: The first five years. Percept Mot Skills 85:531-546, 1997.